Click image above to view full announcement. About IFB-088 (INN: Icerguastat) IFB-088 is a first-in-class orally available small molecule drug candidate with a validated mechanism of action and a ...
The study shows that IFB-088 significantly reduces TDP-43 cytoplasmic mislocalization--a hallmark in the vast majority of ALS cases--and improves both motor neuron survival and motor function in ...
Nantes, France--(Newsfile Corp. - February 6, 2025) - InFlectis BioScience SAS, a drug discovery company pioneering development of therapeutics harnessing the Integrated Stress Response (ISR) for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results